42.89 USD
▲-1.75+7.68%
盘后 39.85 +0.05%
2026-08-03
市值
$2.68B
市盈率
—
EPS
-4.16
股息率
—
52 周区间
6.42 – 47.84
成交量
709.01K
Beta
2.21
目标价
65.00
52W 低 6.4252W 高 47.84
价格走势
公司简介
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...